Your browser doesn't support javascript.
loading
Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma.
Cleary, James M; Rouaisnel, Betty; Daina, Antoine; Raghavan, Srivatsan; Roller, Lauren A; Huffman, Brandon M; Singh, Harshabad; Wen, Patrick Y; Bardeesy, Nabeel; Zoete, Vincent; Wolpin, Brian M; Losman, Julie-Aurore.
Affiliation
  • Cleary JM; Dana-Farber/Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA. james_cleary@dfci.harvard.edu.
  • Rouaisnel B; Dana-Farber/Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Daina A; SIB Swiss Institute of Bioinformatics, Molecular Modeling Group, Lausanne, Switzerland.
  • Raghavan S; Dana-Farber/Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Roller LA; Brigham and Women's Hospital, Department of Radiology, Harvard Medical School, Boston, MA, USA.
  • Huffman BM; Dana-Farber/Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Singh H; Dana-Farber/Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Wen PY; Dana-Farber/Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Bardeesy N; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
  • Zoete V; SIB Swiss Institute of Bioinformatics, Molecular Modeling Group, Lausanne, Switzerland.
  • Wolpin BM; University of Lausanne, Department of Oncology UNIL-CHUV, Ludwig Lausanne Branch, Lausanne, Switzerland.
  • Losman JA; Dana-Farber/Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
NPJ Precis Oncol ; 6(1): 61, 2022 Sep 02.
Article in En | MEDLINE | ID: mdl-36056177
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Language: En Journal: NPJ Precis Oncol Year: 2022 Type: Article Affiliation country: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Language: En Journal: NPJ Precis Oncol Year: 2022 Type: Article Affiliation country: United States